Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
Year: 2022
Type: article
Study design: Observational Study
Source: Blood
Authors: Ofir Wolach, Jacqueline S. Garcia, Pinkal Desai, Pankit Vachhani, Joshua F. Zeidner, Sameem Abedin, Kendra Sweet, Catherine Lai, Yakir Moshe, Daniel A. Pollyea, Marin Xavier, Boaz Nachmias, Tsila Zuckerman, Sangmin Lee, Evan C. Chen, Srilakshmi Bathini, Wesleigh Edwards, Cat N. Bui, Wei-Han Cheng, Catherine Miller, Annie Guerin, Jessica Maitland, Esprit Ma, Melissa Montez, Moshe Grunspan, Aaron D Goldberg
Institutions: Rabin Medical Center, Dana-Farber Cancer Institute, Weill Cornell Medicine, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Medical College of Wisconsin, Moffitt Cancer Center, University of Pennsylvania, Tel Aviv Sourasky Medical Center, University of Colorado Anschutz, Scripps MD Anderson Cancer Center, Hadassah Medical Center, Rambam Health Care Campus, AbbVie (United States), Concordia University, Genentech, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310127366